Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mikus

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
British Journal of Clinical Pharmacology|November 1, 1989
Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotypeA S Gross, G Mikus, C Fischer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 21, 2000
In vitro interaction of codeine and diclofenacS Ammon, O von Richter, U Hofmann, et al.
BMJ (Clinical Research Ed.)|November 19, 1988
Is there a genetic factor in flecainide toxicity?J Beckmann, R Hertrampf, U Gundert-Remy, et al.
Clinical Pharmacology and Therapeutics|May 1, 1989
The influence of the sparteine/debrisoquin phenotype on the disposition of flecainideG Mikus, A S Gross, J Beckmann, et al.
British Journal of Clinical Pharmacology|July 17, 2001
Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysisJ A Webb, A Rostami-Hodjegan, R Abdul-Manap, et al.
Pain|August 1, 1997
Loss of analgesic effect of morphine due to coadministration of rifampinM F Fromm, K Eckhardt, S Li, et al.
Arzneimittel-Forschung|April 1, 1997
Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]. 1st communication: in vivo demonstration of the effects on animal models of cough and of mucociliary clearanceE G Mikus, J Révész, E Minker, et al.
Clinical Pharmacology and Therapeutics|November 20, 2009
Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activityV Hafner, M Jäger, A-K Matthée, et al.
International Journal of Surgery (London, England)|May 16, 2020
No alteration of Cyp3A4 activity after major hepatectomy in the early postoperative period - A prospective before-after studyJ Jedamzik, J Mühlbacher, F Fitschek, et al.
European Journal of Pharmacology|December 11, 2012
Evaluation of SSR161421, a novel orally active adenosine A3 receptor antagonist on pharmacology modelsEndre G Mikus, Judit Szeredi, Kinga Boer, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
British Journal of Clinical Pharmacology|November 1, 1989
Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotypeA S Gross, G Mikus, C Fischer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 21, 2000
In vitro interaction of codeine and diclofenacS Ammon, O von Richter, U Hofmann, et al.
BMJ (Clinical Research Ed.)|November 19, 1988
Is there a genetic factor in flecainide toxicity?J Beckmann, R Hertrampf, U Gundert-Remy, et al.
Clinical Pharmacology and Therapeutics|May 1, 1989
The influence of the sparteine/debrisoquin phenotype on the disposition of flecainideG Mikus, A S Gross, J Beckmann, et al.
British Journal of Clinical Pharmacology|July 17, 2001
Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysisJ A Webb, A Rostami-Hodjegan, R Abdul-Manap, et al.
Pain|August 1, 1997
Loss of analgesic effect of morphine due to coadministration of rifampinM F Fromm, K Eckhardt, S Li, et al.
Arzneimittel-Forschung|April 1, 1997
Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]. 1st communication: in vivo demonstration of the effects on animal models of cough and of mucociliary clearanceE G Mikus, J Révész, E Minker, et al.
Clinical Pharmacology and Therapeutics|November 20, 2009
Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activityV Hafner, M Jäger, A-K Matthée, et al.
International Journal of Surgery (London, England)|May 16, 2020
No alteration of Cyp3A4 activity after major hepatectomy in the early postoperative period - A prospective before-after studyJ Jedamzik, J Mühlbacher, F Fitschek, et al.
European Journal of Pharmacology|December 11, 2012
Evaluation of SSR161421, a novel orally active adenosine A3 receptor antagonist on pharmacology modelsEndre G Mikus, Judit Szeredi, Kinga Boer, et al.
Pageof 9